Substituted amide compounds useful as farnesoid X receptor modulators

US12030835B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Dean A. Wacker · Chadds Ford, US
• Susheel Jethanand Nara · Mumbai, IN
• Srinivas Cheruku · Bengaluru, IN
• Kandhasamy Sarkunam · Hosur, IN
• Firoz Jaipuri · Bengaluru, IN
• Soodamani Thangavel · Krishnagiri, IN
• Rishikesh Narayan · Mumbai, IN
• Subba Reddy Bandreddy · Kanchinakote, IN
• Srinivas Jogi · Kanchinakote, IN
• Pavan Kalyan Kathi · Kanchinakote, IN

Key dates

• Filing date: Feb 14, 2020
• Grant date: Jul 9, 2024
• Expiry date: Jul 3, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.